Cancer immunotherapeutics specialist immatics raises EUR54m
Tuebingen – Private German immunotherapy specialist immatics biotechnologies GmbH has raised EUR53.8 million in a Series C financing round With new funds that the company will use to push its lead cancer vaccine IMA901 into a pivotal Phase III study in advanced renal cell carcinoma (RCC). IMA901 is designed to induce a polyclonal antibody response by 10 different so-called tumour-associated peptides (TUMAPs) that are frequently found to be over-expressed in a large subgroup of patients with renal cell carcinoma. The company said it expects to have first results from the trial (with overall survival as primary endpoint) at the end of 2013. Immatics, which was spun-off from Tuebingen University, also said it will advance its Phase II colorectal cancer vaccine IMA910 and its preclinical project IMA950 in patients with glioblastoma. The financing round was supported by both existing and new investors. Approximately half of the funds came from dievini Hopp Biotech holding, Wellington Partners and other existing shareholders, the other half coming from new investors MIG-advised funds and AT Impf GmbH.